ASX:BOT - Botanix Pharmaceuticals Stock Price, News, & Analysis

+0.02 (+8.89 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: A$0.25
50-Day Range
MA: A$0.17
52-Week Range
Now: A$0.25
Volume3.56 million shs
Average Volume4.45 million shs
Market Capitalization$189.42 million
P/E RatioN/A
Dividend YieldN/A
Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. Botanix Pharmaceuticals Limited is based in Perth, Australia.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales$4.67 million
Cash FlowA$0.02 per share
Book ValueA$0.02 per share



Market Cap$189.42 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BOT News and Ratings via Email

Sign-up to receive the latest news and ratings for BOT and its competitors with MarketBeat's FREE daily newsletter.

Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions

What is Botanix Pharmaceuticals' stock symbol?

Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."

Has Botanix Pharmaceuticals been receiving favorable news coverage?

Media stories about BOT stock have trended extremely negative on Friday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Botanix Pharmaceuticals earned a coverage optimism score of -4.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. View News Stories for Botanix Pharmaceuticals.

Who are some of Botanix Pharmaceuticals' key competitors?

What other stocks do shareholders of Botanix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include Harmony Gold Mining (HMY), Vanadiumcorp Resource (VRB) and Cobalt 27 Capital (KBLT).

Who are Botanix Pharmaceuticals' key executives?

Botanix Pharmaceuticals' management team includes the folowing people:
  • Mr. Matthew Callahan, Founder & Exec. Director (Age 46)
  • Dr. Michael Thurn Ph.D., COO & Exec. Director
  • Dr. Henry William Bosch, Chief Scientific Officer & Exec. Director
  • Dr. Stephane Levy, Chief Medical Officer
  • Mr. Simon Robertson B.Bus, M Appl. Fin, CA, Company Sec.

What is Botanix Pharmaceuticals' stock price today?

One share of BOT stock can currently be purchased for approximately A$0.25.

How big of a company is Botanix Pharmaceuticals?

Botanix Pharmaceuticals has a market capitalization of $189.42 million and generates $4.67 million in revenue each year. Botanix Pharmaceuticals employs 10 workers across the globe.View Additional Information About Botanix Pharmaceuticals.

What is Botanix Pharmaceuticals' official website?

The official website for Botanix Pharmaceuticals is

How can I contact Botanix Pharmaceuticals?

Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.

MarketBeat Community Rating for Botanix Pharmaceuticals (ASX BOT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Botanix Pharmaceuticals and other stocks. Vote "Outperform" if you believe BOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel